CD274 and head and neck squamous cell carcinoma: In a 46-year-old male with relapsed PDL1 positive HNSCC, Schwab et al. [21] showed that the combination ipilimumab plus nivolumab induced a partial response after 8 weeks from the start of treatment and complete response after 4 months of therapy.